ICER Boosts ‘Cost-Recovery’ Benchmark Price For Remdesivir To Reflect Gilead’s Planned R&D

 
• By Cathy Kelly
Coronavirus dollar bill
Price Modeling A Challenge In Rapidly Changing Environment

More from Market Access

More from Pink Sheet